Because gp120/CXCR4-induced lymphocyte death leads to pathological immunodeficiency, a lot of research is still ongoing to identify a CXCR4 antagonist that would selectively prevent the gp120/CXCR4 interaction and thereby HIV-triggered disease progression (204). Here, CXCR4 is linked to immune system disorder.